Selected publications

Antibody Platform

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Laura E. Rosen, M. Alejandra Tortorici, Anna De Marco, et al.
Cell, 2024

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA).
Tan SK, Cebrik D, Plotnik D, Agostini ML, Boundy K, Hebner CM, Yeh WW, Pang PS, Moya J, Fogarty C, Darani M, Hayden FG.
Clin Infect Dis. 2024

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
Plotnik D, Sager JE, Aryal M, Fanget MC, Peter A, Schmid MA, Cebrik D, Mogalian E, Boundy K, Yeh WW, Griffin P, Reyes M.
Antimicrob Agents Chemother. 2024

Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase 3 COMET-ICE Study
Sambhavi Subramanian, Gretja Schnell, Julia di Iulio, et al.
Future Medicine, 2023

Neutralization, Effector Function and Immune Imprinting of Omicron Variants
Amin Addetia, Luca Piccoli, James Brett Case, et al.
Nature, 2023

Potent Broadly Neutralizing Antibody VIR-3434 Controls Hepatitis B and D Virus Infection and Reduces HBsAg in Humanized Mice
Florian A Lempp, Tassilo Volz, Elisabetta Cameroni, et al.
Journal of Hepatology, 2023

A Pan-Influenza Antibody Inhibiting Neuraminidase via Receptor Mimicry
Corey Momont, Ha V. Dang, Fabrizia Zatta, et al.
Nature, 2023

Pandemic Preparedness Strategies Must Go Beyond Vaccines
Rajesh Gupta, Lisa A. Purcell, Davide Corti, et al.
Science Translational Medicine, 2023

Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19: A Randomized Non-inferiority Clinical Trial
Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, et al.
medRxiv, 2023

Population Pharmacokinetics and Exposure-Response Analysis of a Single Dose of Sotrovimab in the Early Treatment of Patients with Mild to Moderate COVID-19
Jennifer E. Sager, Asma El-Zailik, Julie Passarell, et al.
CPT: Pharmacometrics & Systems Pharmacology, 2023

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
Jaynier Moya, Marisol Temech, Sergio Parra, et al.
medRxiv, 2023

Antiviral Agents Against Omicron Subvariant BA.4.6 In Vitro
Jill Walker, Gretja Schnell & William Kerr
NEJM, 2023

The NIH-Led Research Response to COVID-19
Francis Collins, Stacey Adam, Christine Colvis, et al.
Science, 2023

Maturation of SARS-CoV-2 Spike-Specific Memory B Cells Drives Resilience to Viral Escape
Roberta Marzi, Jessica Bassi, Chiara Silacci-Fregni, et al.
iScience, 2022

Natural Heteroclytic-Like Peptides are Generated by SARS-CoV-2 Mutations
Camilla Tiezzi, Andrea Vecchi, Marzia Rossi, et al.
bioRxiv, 2022

Imprinted Antibody Responses Against SARS-CoV-2 Omicron Sublineages
Young-Jun Park, Dora Pinto, Alexandra C Walls, et al.
Science, 2022

The Potent Broadly Neutralizing Antibody VIR-3434 Controls Hepatitis B and D Virus Infection and Reduces HBsAg in Humanized Mice
Florian A. Lempp, Tassilo Volz, Elisabetta Cameroni, et al.
bioRxiv, 2022

Antibody Therapy Reverses Biological Signatures of COVID-19 Progression
M. Cryus Maher, Leah B. Soriaga, Anil Gupta, et al.
Cell Reports Medicine, 2022

ACE2-Binding Exposes the SARS-CoV-2 Fusion Peptide to Broadly Neutralizing Coronavirus Antibodies
Jun Siong Low, Josipa Jerak, M. Alejandra Tortorici, et al.
Science, 2022

Structure of the Rabies Virus Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
Heather M. Callaway, Dawid Zyla, Florence Larrous, et al.
Science Advances, 2022

Structure, Receptor Recognition and Antigenicity of the Human Coronavirus CCoV-HuPn-2018 Spike Glycoprotein
M. Alejandra Tortorici, Alexandra C Walls, Anshu Joshi, et al.
Cell, 2022

The Dual Function Monoclonal Antibodies VIR-7831 and VIR-7832 Demonstrate Potent In Vitro and In Vivo Activity Against SARS-CoV-2
Andrea L. Cathcart, Colin Havenar-Daughton, Florian A. Lempp, et al.
bioRxiv, 2022

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients with Mild to Moderate COVID-19
Anil Gupta, MD, Yaneicy Gonzalez-Rojas, MD, Erick Juarez, MD, et al.
JAMA, 2022

Poor Neutralization and Rapid Decay of Antibodies to SARS-CoV-2 Variants in Vaccinated Dialysis Patients
Jessica Bassi, Olivier Giannini, Chiara Silacci-Fregni, et al.
PLOS One, 2022

Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement
Matthew McCallum, Nadine Czudnochowski, Laura E Rosen, et al.
Science, 2022

Predicting the Mutational Drivers of Future SARS-CoV-2 Variants of Concern
M. Cyrus Maher, Istvan Bartha, Steven Weaver, et al.
Science Translational Medicine, 2022

Antibody-Mediated Broad Sarbecovirus Neutralization through ACE2 Molecular Mimicry
Young-Jun Park, Anna De Marco, Tyler N Starr, et al
Science, 2022

Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift
Elisabetta Cameroni, Christian Saliba, John E. Bowen, et al.
Nature, 2021

Molecular Basis of Immune Evasion by the Delta and Kappa SARS-CoV-2 Variants
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
Science, 2021

Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
medRxiv, 2021

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
NEJM, 2021

Defective Neutralizing Antibody Response to SARS-CoV-2 in Vaccinated Dialysis Patients
Jessica Bassi, Olivier Giannini, Chiara Silacci-Fregni, et al.
medRxiv, 2021

Broad Betacoronavirus Neutralization by a Stem Helix–Specific Human Antibody
Dora Pinto, Maximilian M. Sauer, Nadine Czudnochowski, et al.
Science, 2021

Lectins Enhance SARS-CoV-2 Infection and Influence Neutralizing Antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature, 2021

Broad Sarbecovirus Neutralization by a Human Monoclonal Antibody
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, et al.
Nature, 2021

SARS-CoV-2 RBD Antibodies that Maximize Breadth and Resistance to Escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature, 2021

After the Pandemic: Perspectives on the Future Trajectory of COVID-19
Amalio Telenti, Ann Arvin, Lawrence Corey, et al.
Nature, 2021

SARS-CoV-2 Immune Evasion by the B.1.427/B.1.429 Variant of Concern
Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
Science, 2021

In Vivo Monoclonal Antibody Efficacy Against SARS-CoV-2 Variant Strains
Rita E. Chen, Emma S. Winkler, James Brett Case, et al.
Nature, 2021

Transfer Transcriptomic Signatures for Infectious Diseases
Julia di Iulioa, Istvan Barthaa, Roberto Spreaficoa, et al
PNAS, 2021

MP-NeRF: A Massively Parallel Method for Accelerating Protein Structure Reconstruction from Internal Coordinates
Eric Alcaide, Stella Biderman, Amalio Telenti, et al
bioRxiv, 2021

Tackling COVID-19 with Neutralizing Monoclonal Antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell, 2021

The Need for Global Access to Biomedical Innovations During Pandemics
Rajesh Gupta
Nature, 2021

N-Terminal Domain Antigenic Mapping Reveals a Site of Vulnerability for SARS-CoV-2
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell, 2021

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-Elicited Antibodies
Dami Collier, Anna De Marco, Isabella Ferreira, et al
Nature, 2021

SARS-CoV-2 B.1.1.7 Escape from mRNA Vaccine-Elicited Neutralizing Antibodies
Dami Collier, Anna De Marco, Isabella Ferreira, et al
medRxiv, 2021

Circulating SARS-CoV-2 Spike N439K Variants Maintain Fitness while Evading Antibody-Mediated Immunity
Emma C Thomson, Laura E Rosen, James G Shepherd, et al
Cell, 2021

Risk Assessment and Seroprevalence of SARS-CoV-2 Infection in Healthcare Workers of COVID-19 and Non-COVID-19 Hospitals in Southern Switzerland
Luca Piccoli, Paolo Ferrari, Giovanni Piumatti, et al.
The Lancet Regional Health - Europe, 2020

Advancing New Tools for Infectious Diseases
Rajesh Gupta
Science, 2020

Fc-Optimized Antibodies Elicit CD8 Immunity to Viral Respiratory Infection
Stylianos Bournazos, Davide Corti, Herbert W. Virgin & Jeffrey V. Ravetch
Nature, 2020

Vir Effector Function Deep Dive.
Vir Biotechnology, Inc., 2020

Antibody Potency, Effector Function and Combinations in Protection from SARS-CoV-2 Infection In Vivo
Alexandra Schäfer, Frauke Muecksch, Julio C. C. Lorenzi, et al
bioRxiv, 2020

Ultrapotent Human Antibodies Protect Against SARS-CoV-2 Challenge via Multiple Mechanisms
M. Alejandra Tortorici, Martina Beltramello, Florian A. Lempp, et al
Science, 2020

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Luca Piccoli, Young-Jun Park, M. Alejandra Tortorici, et al
Cell, 2020

A Combination of Two Human Monoclonal Antibodies Cures Symptomatic Rabies
Guilherme Dias de Melo, Florian Sonthonnax, Gabriel Lepousez, et al
EMBO Molecular Medicine, 2020

A Perspective on Potential Antibody-Dependent Enhancement of SARS-CoV-2
Ann M. Arvin, Katja Fink, Michael A. Schmid, et al
Nature, 2020

Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody
Dora Pinto, Young-Jun Park, Martina Beltramello, et al
Nature, 2020

Developing Therapeutic Monoclonal Antibodies at Pandemic Pace
Brian Kelley
Nature Biotechnology, 2020

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu, M.D. et al
February, 2019

Tackling Influenza with Broadly Neutralizing Antibodies
Davide Corti, Antonio Lanzavecchia
Current Opinion in Virology, 2017

Fcg Receptor Function and the Design of Vaccination Strategies
Stylianos Bournazos and Jeffrey V. Ravetch
Immunity, 2017

Protective Monotherapy Against Lethal Ebola Virus Infection by a Potently Neutralizing Antibody
Davide Corti, Antonio Lanzavecchia, Nancy J. Sullivan
Science, 2016

Cross-Neutralization of Four Paramyxoviruses by a Human Monoclonal Antibody
Davide Corti, Antonio Lanzavecchia
Nature, 2013

PRO-XTEN masking platform

Podust V.N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.
Journal of Controlled Release, 2016

Moore W.V. et al. A randomized safety and efficacy study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency.
The Journal of Clinical Endocrinology and Metabolism, 2016

Ding S. et al. Multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility.
Bioconjugate Chemistry, 2014

Podust V.N. et al. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.
Protein Engineering, Design & Selection, 2013

Yuen K.C.J. et al. A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone deficient adults.
The Journal of Clinical Endocrinology and Metabolism, 2013

Alters S.E. et al. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn’s disease model.
PLoS ONE, 2012

Cleland J.L. et al. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.
Journal of Pharmaceutical Sciences, 2012

Geething N.C. et al. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.
PLoS ONE, 2010.

Schellenberger V. et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.
Nature Biotechnology, 2009

Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics 
AACR-NCI-EORTC Conference, October 2021.

HER2-XPAT, A Novel Protease-Activated Prodrug T Cell Engager (TCE) With Potent T Cell Activation and Efficacy in Solid Tumor Models and Large Predicted Safety Margins in Non-Human Primates.
AACR Virtual Annual Meeting, April 2021.

HER2-XPAT and EGFR-XPAT: Pro-Drug T Cell Engagers (TCEs) Engineered to Address On-Target, Off-Tumor Toxicity With Potent Efficacy in vitro and in vivo and Large Safety Margins in NHP.
AACR Virtual Annual Meeting II, June 2020.

EGFR-XPAT, A Novel Prodrug T Cell Engager (TCE) Engineered to Address On-Target, Off-Tumor Toxicity and an Orthogonal Approach for Cancer Immunotherapy in EGFR, KRAS/BRAF Cancers.
ESMO Virtual Congress, September 2020.

T Cell Platform

CD8+ T Cell Programming by Cytomegalovirus Vectors: Applications in Prophylactic and Therapeutic Vaccination
Klaus Frueh, Louis Picker
Current Opinion in Immunology, 2017

Broadly Targeted CD8+ T Cell Responses Restricted by Major Histocompatibility Complex E
Scott G. Hansen, Louis J. Picker
Science, 2016

Other Research

Large language models for science and medicine
Amalio Telenti, Cyrus Maher, et al
European Journal of Clinical Investigation, 2023

Sponsored Content Addressing the Unmet Need for a Functional Cure for Chronic Hepatitis B
Carey Hwang, Phil Pang, et al
Sponsored Edition Nature Outlook, 2022

Selection of GalNAc-Conjugated siRNAs with Limited Off-Target-Driven Rat Hepatotoxicity
Maja M. Janas, Vasant Jadhav
Nature Communications, 2018

Sphingolipid Biosynthesis Induces a Conformational Change in the Murine Norovirus Receptor and Facilitates Viral Infection
Robert C. Orchard, Herbert W. Virgin
Nature Microbiology, 2018

Discovery of a Proteinaceous Cellular Receptor for a Norovirus
Robert C. Orchard, Herbert W. Virgin
Science, 2016

Molecular Characterization of LC3-Associated Phagocytosis Reveals Distinct Roles for Rubicon NOX2 and Autophagy Proteins
Jennifer Martinez, Herbert W. Virgin, Douglas R. Green
Nature Cell Biology, 2015

Unique Role for ATG5 in Neutrophil-Mediated Immunopathology during M. Tuberculosis Infection
Jacqueline M. Kimmey, Herbert W. Virgin, Christina L. Stallings
Nature, 2015